unknown
Stage
1
Investors
About
InterAx Biotech develops novel small molecule drugs targeting GPCRs using its Deep Signal™ platform, which combines mathematical modeling, experimental methods, and machine learning to understand cellular signaling and improve drug efficacy and safety.
Explore InterAx Biotech AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.